News​

CELLINK and Ossiform Enter a Strategic Partnership to launch Ossi Ink, a printable bioink based on Ossiform’s P3D Bone material

By Ossiform & CELLINK | November 30, 2023 | NEWS​

(November 30, Gothenburg – Odense): CELLINK and Ossiform have entered a strategic partnership to join forces to commercialize a ready-to-print bioink based on Ossiform’s existing biomaterial. Sales of the material will begin in 2024 and will be distributed co-exclusively through CELLINK’s commercial channels.​​

CELLINK and Ossiform look to capitalize on synergies and bring to the market a highly functional bioink for bone-based research. The partnership has scope for additional materials, including clinical grade bioinks. ​

Ossiform raises new capital

By Ossiform | October 05, 2022 | NEWS​

​ODENSE, October 5th, 2022 – Ossiform, We Print Bone™, is pleased to announce that it has completed a £6 million capital raise through West Hill Capital. Ossiform has developed a disruptive and patented technology to produce and supply P3D Bone; 3D printed patient-specific, resorbable bone implants that remodel into real living bone. Positive testing results toward FDA clearance have been obtained, and sales of Ossiform’s 3D printed R&D products for enhancing bone and cancer research, the P3D Scaffolds, have been established internationally.

​CAM Bioceramics and Ossiform team up for OMTEC 2022

By Ossiform | June 03, 2022 | NEWS​

As partners through several years, Ossiform, the developer of proprietary technology to produce natural, patient specific, and resorbable bone implants, and CAM Bioceramics, a leading contract development and manufacturing company of Orthobiologic Calcium Phosphates, have teamed up to showcase their service and product portfolios at OMTEC 2022.

Ossiform - Announces rebrand​

By Ossiform​ | Jan 05, 2022 | NEWS

ODENSE, January 5th, 2022 – Ossiform, We Print Bone™, is pleased to announce that it has completed its rebranding. With the approaching launch of its first bone implant for human use, the Company has rapidly grown and matured, and the rebranding marks a further step in expanding Ossiform’s commercialization activities

Patent for Ossiform’s technology granted in China

​by Ossiform | Aug 20, 2021 | NEWS​

August 10th 2021, the China National Intellectual Property Administration (CNIPA) announced that Ossiform’s patent, Feedstock for 3D printing and uses thereof no. PCT/DK2016/050323, has been granted in China.​

Ossiform – New market-oriented Chairman of the Board

​by Ossiform | June 1, 2021 | NEWS​

​ODENSE, 1st June 2021 – Ossiform, We Print Bone™, is pleased to announce that a new and highly qualified Chairman of the Board has been found.

The Company appoints Mette-Marie Harild as new Chairman of the Board if she is elected to the board of directors at Ossiform Limited’s general meeting which will take place on 15th June 2021.

New research paper: Treating mouse skull defects with 3D-printed fatty acid and tricalcium phosphate implants

​by Ossiform | Nov 13, 2020 | NEWS​

View the results of the new peer-reviewed paper on the performance of P3D Bone as a novel form of individualized ceramic bone implants.​

Patent for Ossiform’s technology granted in the USA

​by Ossiform | Jun 10, 2020 | NEWS​

June 9th 2020, the United States Patent and Trademark office (USPTO) announced that Ossiform’s patent, Feedstock for 3D printing and uses thereof no. PCT/DK2016/050323, has been granted in the USA.

This marks Ossiform’s second patent issuance, following the approval and publication of its European patent, EP/3359318, in April 2020.​

Ossiform raises capital through West Hill

​by Ossiform | May 18, 2020 | NEWS​

ODENSE, May 18th, 2020 – Ossiform, We Print Bone™, is pleased to announce that the £2.5 million capital raise through West Hill Capital was heavily oversubscribed. Ossiform has developed a disruptive and patented technology to be used to produce and supply P3D Bone; 3D printed patient-specific, resorbable bone implants that remodel into real living bone. The first research products have been launched, the P3D Scaffolds, bringing natural bone environments into laboratories.​

Ossiform enters U.S. partnership with Asimov Ventures

​by Ossiform | May 4, 2020 | NEWS​

Ossiform receives investment from New York based venture capital firm, Asimov Ventures, and enters valuable U.S. partnership. The partnership with Asimov Ventures marks the Company’s first step into the U.S. market, looking toward an early commercialization of P3D Bone in the USA.​

That's why, We Print Bone

Our mission is to provide 3D printed natural bone implants to reduce complications, improve functional outcomes, and obtain faster recovery

Tailored properties, optimized for bone regeneration and relevant biomechanical thresholds

Fully remodels into new vascularized bone, tuned to offer balanced rates of resorption and new bone ingrowth

Patient matched designed with the patient's uniqueness and biomechanical factors in mind

Resorbable material with structural support, offering controlled cortical and cancellous components

P3D Bone Extremities – approval process ongoing

Our first 3D printed, resorbable P3D Bone with modifiable dimensions and a bone-like morphology

P3D Bone - under development

The next generation of resorbable and structural bone implants

We Print Bone​™

Contact us here

Contact us for questions, general inquiries, or to request a quote.
We strive to provide you with highest quality service and expertise in medical 3D printing.

 
 
 
Please make sure all required fields are filled out correctly

Do you have questions?

Give us a call or send us an email: info@ossiform.com

We will get back to you as soon as possible.​

logo - hvid u. baggrund

Ossiform ApS - We Print Bone™

​Oslogade 1, 5000 Odense C​, Denmark

CVR. 38838512

  youtube (1)  facebook  linkedin  twitter_2  instagram

Copyright © 2024 Ossiform​. All rights reserved.